Full-Time

Tissue Recovery Specialist

StimLabs

StimLabs

51-200 employees

Develops and sells placental tissue therapies

No salary listed

Jackson, TN, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Inventory Management
Excel/Numbers/Sheets
Requirements
  • Bachelor's Degree preferred.
  • Experience with Excel and Microsoft Teams preferred.
  • 1-2 years of relevant experience
Responsibilities
  • Provides key Beyond Birth program support to Hospitals and the StimLabs organization.
  • Act as an acquisition representative, promoting high standards and education.
  • Assist or lead Beyond Birth projects as assigned by management.
  • Ensure all Beyond Birth activities and documentation comply with internal policies, AATB standards, and FDA regulations.
  • Develop and maintain positive relationships with medical partners, hospitals, and StimLabs employees.
  • Participate in daily acquisition activities, including weekend rotations.
  • Propose and implement improvements for the Beyond Birth program, Quality System, and department.
  • Acquire and clarify donor information as requested.
  • Coordinate with hospital and physician staff for complete donor records.
  • Ensure donor records are timely, accurate, and compliant with StimLabs, FDA, and AATB standards.
  • Review donor records for eligibility.
  • Request medical records and follow-up information.
  • Provide donation education, obtain consent, and conduct risk assessment interviews.
  • Apply aseptic techniques for donor storage.
  • Prepare and submit serology requisitions and blood samples.
  • Package and ship donated tissue and specimens including procurement cultures
  • Order, manage, and maintain supplies.
  • Maintain sanitary workstations and equipment. This includes regular cleaning of storage areas like refrigerators and freezers.
  • Assist with investigations and documentation of CAPAs, Deviations, Nonconformance Reports, and Complaints.
  • Collaborate on the development of Standard Operating Procedures, Work Instructions, Forms, sampling plans, and specifications.
  • Collaborate with Donor Services for investigations and documentation.
  • Review procedures for efficiency improvements.
  • Assist with training new employees and hospital personnel.
  • Coordinate responses and resolutions with internal and external parties.
  • Maintain positive working relationships.
  • Prioritize tasks to ensure timely completion.
  • Perform related duties as assigned.

StimLabs focuses on developing, producing, and selling placental tissue–based products that support regenerative healing for patients. These products are used by healthcare providers, hospitals, and clinics to help repair damaged tissues. They work by using proprietary processing techniques to prepare placental tissue into medical materials that can be applied to wounds or injured areas to promote tissue regeneration and healing. What sets StimLabs apart from competitors is its ownership of proprietary processing methods and a strong emphasis on regulatory compliance and quality control, which helps ensure safety and reliability for clinicians and patients. The company’s goal is to advance regenerative medicine by providing trusted placental tissue products that improve patient outcomes and become a preferred partner for healthcare providers.

Company Size

51-200

Company Stage

Seed

Total Funding

$10M

Headquarters

Roswell, Georgia

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Advanced wound care market grows from $7.77B in 2024 to $13.04B by 2032.
  • Relese dCHPM allograft improved hard-to-heal wound closure in November 2025 trial.
  • Mölnlycke partners as exclusive provider for CAMPSTIM diabetic ulcer trial.

What critics are saying

  • MiMedx Medicare coverage erodes StimLabs placental product market share.
  • Organogenesis Apligraf blocks Allacor P formulary inclusion with Level 1 evidence.
  • FDA reclassifies amniotic devices as biologics, devaluing StimLabs processing IP.

What makes StimLabs unique

  • Allacor P is first FDA 510(k)-cleared human umbilical cord particulate device.
  • Architect Fx uses proprietary BriDGE technology from equine pericardium.
  • Exclusive US distribution rights for Geistlich's Derma-Gide xenograft.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Flexible Work Hours

Company News

PR Newswire
Mar 3rd, 2026
StimLabs launches Architect Fx collagen matrix for chronic and complex wound treatment

StimLabs, a regenerative medicine company, has launched Architect Fx, an advanced collagen matrix device for wound management derived from equine pericardium. The product received FDA 510(k) clearance for treating chronic diabetic, venous and pressure ulcers, as well as traumatic and surgical wounds. The device uses proprietary BriDGE technology to create a durable extracellular matrix that resists degradation and supports reapplications and extended wear. This allows clinicians to adapt treatment based on wound condition and healing progress. Distribution of Architect Fx began in Q1 2026. The launch supports StimLabs' strategy to expand its commercial footprint and product portfolio in the advanced wound care market, according to Tom Dion, the company's executive vice president and chief commercial officer.

PR Newswire
Feb 12th, 2026
StimLabs gains FDA clearance for DermaForm collagen wound care device

StimLabs, a regenerative medicine company, has received FDA 510(k) clearance for DermaForm, a collagen scaffold particulate wound care device developed with Geistlich. The extracellular matrix product is designed to protect and manage chronic and acute wounds. The clearance strengthens StimLabs' portfolio of wound care solutions. Tom Dion, the company's EVP and chief commercial officer, said DermaForm represents the company's ongoing commitment to innovation and bringing meaningful products to market. StimLabs, which focuses on wound care and surgical applications, developed DermaForm through its collaboration with Geistlich, a Swiss family-owned company and global leader in regenerative medicine. The partnership aims to deliver advanced solutions that enhance outcomes and improve quality of life for patients with complex wounds.

Medical Device Network
Jan 6th, 2026
StimLabs launches Allacor P for acute and chronic wound care

StimLabs launches Allacor P for acute and chronic wound care. Allacor P retains key ECM components, including collagen I and hyaluronic acid. StimLabs has announced the launch of Allacor P, a human umbilical cord device designed for acute and chronic wound management. The device received clearance from the US Food and Drug Administration (FDA) in February 2024 with the hospital solution Corplex P, which is derived from umbilical cord tissue. It claims to be the first graft derived from the human umbilical cord extracellular matrix (ECM) and is indicated for a broad spectrum of wounds. The device features a particulate format that adapts to irregular and complex wound surfaces. Allacor P retains key ECM components, including collagen I and hyaluronic acid. According to Stimlabs, this composition supports the application process across various clinical scenarios. US tariffs are shifting - will you react or anticipate? Don't let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. Last year, the product received an A Code, enabling its introduction into additional care sites. Since receiving clearance, StimLabs has focused on building scientific evidence and gathering clinical feedback from real-world use cases to support informed application of the product as it expands into new healthcare settings. StimLabs wound care clinician Dr R Daniel Davis said: "The dehydrated human umbilical cord particulate device has the potential to impact so many patients in the same way it did for a recent complex case of mine. "The dramatic improvement after just one application brought hope to my patient during a challenging time. I'm an advocate for this device; it's something providers need to try." The company's operations are currently centred on regenerative medicine with emphasis on wound care and surgical applications. In November 2025, StimLabs reported findings from a multi-centre trial of its fenestrated dehydrated complete human placental membrane (dCHPM) allograft, Relese, when used alongside standard of care for wounds that are hard to heal.

Medical Device Network
Nov 28th, 2024
Geistlich Pharma partners with StimLabs for wound care distribution in US

Geistlich Pharma has entered an exclusive national distribution collaboration agreement with StimLabs in the US, focusing on the commercialisation of the former's Advanced Wound Matrix, Derma-Gide.

Business Wire
Nov 26th, 2024
Geistlich Announces Exclusive Distribution Partnership for its Leading Wound Care Portfolio in the United States

WOLHUSEN, Switzerland-(BUSINESS WIRE)-Geistlich Pharma AG, a worldwide leader in regenerative technologies, announced an exclusive national distribution partnership agreement with StimLabs of Roswell, GA.